Ipca Laboratories Limited
IPCALAB
Clasificación en acciones
#3408
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Precio por acción
$20.16
Capitalización bursátil
$5.12B
Cambio (1 día)
0.68%
Cambio (1 año)
38.50%
País
IN
Comercio Ipca Laboratories Limited (IPCALAB)
Categoría
Healthcare
Ingresos de Ipca Laboratories Limited (IPCALAB)
Ingresos en Jun 2026 TTM: $1.12B
Según los últimos informes financieros de Ipca Laboratories Limited, los ingresos actuales de la empresa (TTM) son $1.12B. En 2024, la empresa obtuvo unos ingresos de $924.15M un aumento con respecto a los ingresos del año 2023, que fueron de $760.29M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Ipca Laboratories Limited desde 2005 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.12B | 6.89% |
| 2025 | $1.05B | 13.12% |
| 2024 | $924.15M | 21.55% |
| 2023 | $760.29M | -1.02% |
| 2022 | $768.09M | 3.73% |
| 2021 | $740.50M | 19.97% |
| 2020 | $617.22M | 13.54% |
| 2019 | $543.63M | 7.74% |
| 2018 | $504.56M | 3.67% |
| 2017 | $486.70M | 12.46% |
| 2016 | $432.77M | -14.12% |
| 2015 | $503.92M | -7.96% |
| 2014 | $547.51M | 5.75% |
| 2013 | $517.74M | 11.30% |
| 2012 | $465.16M | 9.12% |
| 2011 | $426.30M | 22.77% |
| 2010 | $347.24M | 37.32% |
| 2009 | $252.88M | -3.75% |
| 2008 | $262.72M | 21.27% |
| 2007 | $216.64M | 27.04% |
| 2006 | $170.53M | 9.66% |
| 2005 | $155.51M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 491.67% |
IN
|
